In an exciting milestone for global health and HIV prevention, Dr. Flavia Matovu Kiweewa has been recognized for her contribution to the development of Lenacapavir, a groundbreaking drug recently approved by the U.S. Food and Drug Administration (FDA) for HIV prevention treatment.

Dr. Flavia has long been a beacon of excellence in medical research, particularly in the field of HIV/AIDS. Her tireless dedication to improving public health has now earned her global recognition, reaffirming the critical role that African scientists and clinicians play in advancing healthcare worldwide.

Lenacapavir is a long-acting injectable medication that offers a promising alternative for individuals at risk of HIV infection. Its approval marks a significant advancement in prevention strategies, with the potential to greatly enhance adherence and reduce new infections. Dr. Flavia’s involvement in its research and development is a testament to her expertise, leadership, and unwavering commitment to ending the HIV epidemic.

The Gayaza Old Girls Association (GOGA) has proudly celebrated her achievement, noting how her work continues to inspire generations of women in science. Their message reads:
“Congratulations Dr. Flavia! You have done us proud.”

As we mark this moment, we also look forward to what lies ahead. Dr. Flavia remains deeply engaged in ongoing research, mentoring young scientists, and advocating for equitable access to lifesaving treatments.

To every young girl in Uganda and beyond dreaming of changing the world through science—Dr. Flavia Matovu Kiweewa’s journey is proof that it is possible.